Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Apache Indian who wrote (624)	8/2/1999 11:07:00 AM
From: BRAVEHEART	Read Replies (1) of 1494

Buyout Hi Apache, I never see that as a near term event. NTI is essentially welded to MERZ. I suppose MERZ could be a contender but I don't see where it would be to NTI's advantage to sell unless it could do so in a competitive arena. That arena does not exist IMO. The good side is up-side. NTI was rumored to have a buyout offer a year ago of $1.75...That clearly would remove all risk & settle once & for all anyones interests here. But today $1.75 looks pathetic given NTI's leverage relationship with MERZ. Sure the risk still exists but the upside is better than ever. I still am digging around the issue as to how NTI is still operating. Funds ran out in June. Here we are in Aug. This is why I am expecting some sort of low risk announcement on funding. Remember the prior funding involved the likes of A Rock. We moved from .50 to $1.5 in a few days time. Could this recent volume be based on some sort of funding announcement. Did we miss something. Last time Bloomberg carried this news. Anyone check Bloomberg lately? Also MERZ should get it's data this month. Logic has it that Pharma has been waiting on this data to partner. I don't know how long it takes to quantify & qualify such data for a significant understanding. My guess is this will finalize the needed leverage for a Pharma deal. Of course this depends on the data. John do you have any insights on this matter? Should we anticipate results in Aug or Sept? My guess is this leverage could open up new negotiations as well if the results are steller. I still see this as a win win situation for NTI shareholders. It is not company specific. Yet it has the potential to enhance leverage. If it is a no go then we still have NTI's clinical data in the Fall. BEST WISHES Jeffrey

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next